{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T22:01:55Z","timestamp":1785535315959,"version":"3.56.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.bbmt.2017.07.007","type":"journal-article","created":{"date-parts":[[2017,7,13]],"date-time":"2017-07-13T14:47:07Z","timestamp":1499957227000},"page":"1989-1997","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Donor Lymphocyte Infusions Used to Treat Mixed-Chimeric and High-Risk Patient Populations in the Relapsed and Nonrelapsed Settings after Allogeneic Transplantation for Hematologic Malignancies Are Associated with High Five-Year Survival if Persistent Full Donor Chimerism Is Obtained or Maintained"],"prefix":"10.1016","volume":"23","author":[{"given":"Lauren E.","family":"Caldemeyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke P.","family":"Akard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Tandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn R.","family":"Wagenknecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Dugan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2017.07.007_bib0010","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1517\/14712598.2011.554811","article-title":"Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation","volume":"11","author":"Roddie","year":"2011","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.bbmt.2017.07.007_bib0015","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.bbmt.2012.12.013","article-title":"Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes","volume":"19","author":"Krishnamurthy","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.007_bib0020","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1200\/JCO.2010.32.1711","article-title":"Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma","volume":"29","author":"Peggs","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.07.007_bib0025","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2013.08.012","volume":"20","author":"de Lima","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.007_bib0030","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1182\/blood.V76.12.2462.2462","article-title":"Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients","volume":"76","author":"Kolb","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.07.007_bib0035","first-page":"391","article-title":"Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression","volume":"10","author":"Collins","year":"1992","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.007_bib0040","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1182\/blood.V86.4.1261.bloodjournal8641261","article-title":"Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separate of graft-versus-leukemia responses from graft-versus-host-disease","volume":"86","author":"Mackinnon","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.07.007_bib0045","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.V86.5.2041.bloodjournal8652041","article-title":"Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients: European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia","volume":"86","author":"Kolb","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.07.007_bib0050","first-page":"975","article-title":"Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation","volume":"18","author":"Porter","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.007_bib0055","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/JCO.1997.15.2.433","article-title":"Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation","volume":"15","author":"Collins","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.07.007_bib0060","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/JCO.2002.20.2.405","article-title":"Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation","volume":"20","author":"Levine","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.07.007_bib0065","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1200\/JCO.2007.11.6053","volume":"25","author":"Schmid","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.07.007_bib0070","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1200\/JCO.2009.27.1460","article-title":"Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia","volume":"28","author":"Gyurkocza","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.07.007_bib0075","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/MOH.0b013e3280168462","article-title":"Hematopoietic cell transplantation after reduced-intensity conditioning for older adults with acute myeloid leukemia in complete remission","volume":"14","author":"Baron","year":"2007","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.bbmt.2017.07.007_bib0080","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/bbmt.2002.v8.pm12171484","article-title":"Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide","volume":"8","author":"O'Donnell","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.007_bib0085","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/sj.bmt.1704715","article-title":"How and when should we monitor chimerism after allogeneic stem cell transplantation?","volume":"35","author":"Bader","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.007_bib0090","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.bbmt.2014.05.025","article-title":"Donor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survival","volume":"20","author":"Koreth","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.007_bib0095","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/bmt.2008.212","article-title":"Mixed chimerism in SCT: conflict or peaceful coexistence?","volume":"42","author":"Liesveld","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.007_bib0100","first-page":"801","article-title":"Chimerism status is a useful predictor of relapse after allogeneic stem cell transplantation for acute leukemia","volume":"88","author":"Barrios","year":"2003","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2017.07.007_bib0105","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.bbmt.2014.12.029","article-title":"Chimerism-based pre-emptive immunotherapy with fast withdrawal of immunosuppression and donor lymphocyte infusions after allogeneic stem cell transplantation for pediatric hematologic malignancies","volume":"21","author":"Horn","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.007_bib0110","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/sj.bmt.1705582","article-title":"Chimerism analysis within 6 months of allogeneic stem cell transplantation predicts relapse in acute myeloid leukemia","volume":"39","author":"Huisman","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.007_bib0115","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.blre.2012.11.002","article-title":"Donor lymphocyte infusions for relapse after allogeneic transplantation: when, if and for whom?","volume":"27","author":"Chang","year":"2013","journal-title":"Blood Rev"},{"key":"10.1016\/j.bbmt.2017.07.007_bib0120","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","article-title":"Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors","volume":"18","author":"Glucksberg","year":"1974","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2017.07.007_bib0125","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1046\/j.1365-2141.1997.1112925.x","article-title":"IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade","volume":"97","author":"Rowlings","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2017.07.007_bib0130","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/0002-9343(80)90380-0","article-title":"Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients","volume":"69","author":"Shulman","year":"1980","journal-title":"Am J Med"},{"key":"10.1016\/j.bbmt.2017.07.007_bib0135","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1182\/blood.V95.1.67","article-title":"Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia","volume":"95","author":"Dazzi","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.07.007_bib0140","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.bbmt.2014.07.010","volume":"20","author":"Takami","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.007_bib0145","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.bbmt.2013.03.001","article-title":"Donor lymphocyte infusion for relapse hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose","volume":"19","author":"Bar","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.007_bib0150","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.bbmt.2013.11.020","article-title":"HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation","volume":"20","author":"Zeidan","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.007_bib0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2017.02.012","article-title":"Donor lymphocyte infusion for relapsed hematological malignancies after unrelated allogeneic bone marrow transplantation facilitated by the Japan Marrow Donor Program","author":"Miyamoto","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.007_bib0160","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1182\/blood.V96.8.2712","article-title":"Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia","volume":"96","author":"Dazzi","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.07.007_bib0165","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.bmt.1705074","article-title":"Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation","volume":"36","author":"Russell","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.007_bib0170","first-page":"1214","article-title":"Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions","volume":"95","author":"Porter","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.07.007_bib0175","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1038\/sj.leu.2403523","article-title":"Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse","volume":"18","author":"Choi","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2017.07.007_bib0180","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.transci.2016.05.011","article-title":"Donor lymphocyte infusion after allogeneic stem cell transplantation","volume":"54","author":"Castagna","year":"2016","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.bbmt.2017.07.007_bib0185","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.bbmt.2013.02.005","article-title":"Finding the sweet spot for donor lymphocyte infusions","volume":"19","author":"Yun","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.007_bib0190","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/bmt.2015.234","article-title":"Long-term results of adjuvant donor lymphocyte transfusion in AML after allogeneic stem cell transplantation","volume":"51","author":"Jedlickova","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.007_bib0195","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.bbmt.2012.07.021","article-title":"High alloreactivity of low-dose prophylactic donor lymphocyte infusion in patients with acute leukemia undergoing allogeneic hematopoietic cell transplantation with an alemtuzumab-containing conditioning regimen","volume":"19","author":"Liga","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.007_bib0200","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1200\/JCO.2009.26.9100","article-title":"T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma","volume":"28","author":"Thomson","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.07.007_bib0205","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/bmt.2016.326","article-title":"Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation for high-risk AML","volume":"52","author":"Legrand","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.007_bib0210","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/bmt.2013.111","article-title":"Myeloablative T cell-depleted alloSCT with early sequential prophylactic donor lymphocyte infusion is an efficient and safe post-remission treatment for adult ALL","volume":"49","author":"Eefting","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.007_bib0215","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.bbmt.2014.05.026","article-title":"Comparison of chimerism and minimal residual disease monitoring for relapse prediction after allogeneic stem cell transplantation for adult acute lymphoblastic leukemia","volume":"20","author":"Terwey","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.007_bib0220","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/bmt.2014.227","article-title":"A multicentre UK study of GVHD following DLI: rates of GVHD are high but mortality from GVHG is infrequent","volume":"50","author":"Scarisbrick","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.007_bib0225","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S1083-8791(03)00077-6","article-title":"Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation","volume":"9","author":"Dey","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.007_bib0230","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/bmt.2016.38","article-title":"Prophylactic donor lymphocyte infusion in patients with high-risk acute myeloid leukemia: ready for prime time?","volume":"51","author":"Baron","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.007_bib0235","doi-asserted-by":"crossref","first-page":"751","DOI":"10.3324\/haematol.2013.089565","article-title":"Intentional donor lymphocyte-induced limited acute graft-versus-host disease is essential for long-term survival of relapsed acute myeloid leukemia after allogeneic stem cell transplantation","volume":"99","author":"Eefting","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2017.07.007_bib0240","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1182\/asheducation-2015.1.225","article-title":"Graft-versus-host disease versus graft-versus leukemia","volume":"2015","author":"Negrin","year":"2015","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.bbmt.2017.07.007_bib0245","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1182\/blood-2002-05-1304","article-title":"Prognostic factors for acute graft-versus-host disease after donor lymphocyte infusions","volume":"100","author":"Dazzi","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.07.007_bib0250","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/bmt.2014.2","volume":"49","author":"Solomon","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.007_bib0255","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/j.1365-2141.2008.07260.x","article-title":"Understanding a harnessing the graft-versus-leukaemia effect","volume":"142","author":"Barrett","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2017.07.007_bib0260","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/bmt.2016.63","article-title":"Lymphodepleting chemotherapy with donor lymphocyte infusion post-allogeneic HCT for hematological malignancies is associated with severe, but therapy-responsive aGVHD","volume":"51","author":"He","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.007_bib0265","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1172\/JCI119601","article-title":"Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion","volume":"100","author":"Claret","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bbmt.2017.07.007_bib0270","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1182\/blood-2008-03-077974","article-title":"Graft-versus-leukemia effects of transplantation and donor lymphocytes","volume":"112","author":"Kolb","year":"2008","journal-title":"Blood"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879117305761?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879117305761?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:01:44Z","timestamp":1761058904000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879117305761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":53,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S1083879117305761"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2017.07.007","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Donor Lymphocyte Infusions Used to Treat Mixed-Chimeric and High-Risk Patient Populations in the Relapsed and Nonrelapsed Settings after Allogeneic Transplantation for Hematologic Malignancies Are Associated with High Five-Year Survival if Persistent Full Donor Chimerism Is Obtained or Maintained","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2017.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}